Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do any of you good people know why and for how long Short Analytics is defunct?
fyi BIIB was Denner's second largest holding, after ARIA, now it's his number one holding. See you at that message board?
Thanks so much for your reply. I sold at 23.85. After three and a half years, I just can't take the risk of not locking in a profit. If I miss out on a little from a potential short squeeze, I accept the risk, but I can't emotionally take it going down, from here after the drama of being invested in this stock :)
What does one do in this situation? Does one sell or wait to see if the stock rises from here.
Thanks to everyone on this board who offered their advice and knowledge to a first time investor. Congratulations to everyone here who made a little money, and prayers to all people who suffer from illnesses who may be helped by what Ariad's scientists have to offer. And thank you Alex Denner! I may actually get to take a vacation this summer!
Thank you, sounds good. As they say, if you know options, you're likely to know stocks
http://www.nytimes.com/2006/08/13/business/yourmoney/13stra.html
thank you!
What is the strike price?
http://video.foxbusiness.com/v/5216496254001/?#sp=show-clips
Todd from Endexx on Fox Business News
is anyone curious to follow up with the lawsuit, as a shareholder?
Does anyone have any insight into this new put purchase, per Benzinga:
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) Jan17 12.0 Puts Sweep: 833 @ ASK $1.30: 4001 traded vs 1431 OI: Earnings 11/1 $13.29 Ref
Is this a guarantee that ARIA is heading below 12?
Yes, I had meant to do so but forgot:
http://whalewisdom.com/filer/sarissa-capital-management-lp#/tabholdings_tab_link
between March 2016 and June 2016, Denner's stake in Aria, as a percentage of his Sarissa fund, rose from about 18% to about 27%, following his sale of ABBV
I had a dream where I saw 48
Thank you for clearing that up! Very helpful and constructive post.
someone bought almost 2 million shares at 12.12?
Does anyone know if Timothy Clackson's sales are option related?
Thanks so much! Exciting times to be invested in Aria!
Does anyone have the link to fast money mentioning ARIA today? Thanks so much.
from today's New York Times re: immunotherapy for cancer:
All this has brought new optimism to cancer doctors — a sense that they have begun tapping into a force of nature, the medical equivalent of splitting the atom.
link
http://www.nytimes.com/2016/07/31/health/harnessing-the-immune-system-to-fight-cancer.html?emc=edit_th_20160731&nl=todaysheadlines&nlid=38070082&_r=0
thank you!
Did Aria close at 8.26 or 8.40? Yahoo finance lists 8.40 in after hours; Ameritrade says 8.26
What general counsel announcement? I haven't seen anything and I get email alerts from Ariad
I've had lots of dreams about Aria, of that sort; I've seen $48. I've also dreamed that I have trouble selling in time, to get the best price, which surprises me b/c I've been thinking it would be bought out. Time will tell...
could just be a wise trading move; look how aria is at the top of its current trading range, and short interest is huge, these past 3 days.
That isn't true, they all work. The only things I noticed was that (1) the calendar is clear, following the earnings report this Thursday; (2) the new investor relations contact is their Chief Financial Officer, no longer Maria Cantor. Let's just look forward to a buyout announcement, this Thursday, shall we? God willing.
short interest down, the wee-est bit as of 6/30. Who'd of thought?
Yes and Denner expertly bargained for the option to have Iclusig back in Aria's possession - wise way to conserve money while drugs are in research phase!
http://news.investornetwork.com/2016/06/28/4-biotechs-with-blockbuster-potential-for-multiple-cancer-indications/?1=1&1467120677
Why is nobody talking about this? I think this is why we're not seeing a buyout - the longterm potential will be more profitable, perhaps?
Yes and they don't appear to be looking for a replacement, per Ariad's website. The only jobs available are a handful of science-related positions. Maybe they won't need an investor relations representative soon?
This is helpful information, thank you!
This Friday's analyst's and investor's day has got to be an advertisment for a company for sale, no?
Thank you very much, this is helpful!
I know this all conjecture and there could be a buyout, but does anyone out there have any idea what this good news re: brig might mean for revenues and potential share price?
Safety and Tolerability - All Patients Enrolled
The most common treatment-emergent adverse events (AEs; = 30%), regardless of relationship to treatment, in all patients were nausea (51%), fatigue (42%), diarrhea (41%), headache (34%), and cough (33%).
"The long-term follow up on this clinical trial of brigatinib shows substantial anti-tumor activity with an objective response rate of approximately 72 percent in crizotinib-resistant ALK-positive NSCLC patients," stated D. Ross Camidge, M.D., Ph.D., director of thoracic oncology at the Colorado University Cancer Center. "The median progression-free survival in this post-crizotinib patient group exceeds one-year and has not yet been reached in patients not previously treated with crizotinib. Importantly, no new safety signals have emerged at this later time of follow up."
Study Results
Of the 32 patients with baseline NGS data, 22 (69%) achieved a confirmed objective response on brigatinib.
Of the 9 patients with secondary ALK mutations at baseline, 7 (78%) achieved a confirmed objective response on brigatinib.
Of the 23 patients without secondary ALK mutations at baseline, 15 (65%) achieved a confirmed objective response rate (ORR) on brigatinib.
Of the 6 patients with evaluable tissue samples collected after progression on brigatinib therapy, 5 (83%) were determined to have detectable secondary mutations in the ALK kinase domain. Three out of five of these patients had complex mutation patterns, following responses lasting 5.4, 7.4 and 28.5 months. Two out of five had single secondary ALK kinase domain mutations detected, following responses lasting 10.9 and 11 months.
Of the one patient with a secondary G1202R mutation, the patient achieved a confirmed response on brigatinib and the response is on-going.
"It is encouraging that responses to brigatinib were observed in patients with crizotinib resistant ALK+ lung cancer with and without the presence of ALK resistance mutations. This is consistent with preclinical studies showing brigatinib to be a potent pan-inhibitor of all known ALK secondary resistance mutants," stated Scott N. Gettinger, M.D., associate professor of medicine at Yale Cancer Center.
Aria has released results to be reported at ASCO on their website (investor relations)
Has anyone mentioned the golden cross in Aria's chart?